NCT03344692View on ClinicalTrials.gov

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Type2 Diabetes
Interventions
DRUG

Alirocumab

prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution

OTHER

Placebo

prefilled pen containing 1 ml of solution without Praluent

Trial Locations (1)

44093

University Hospital of Nantes, Nantes

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Nantes University Hospital

OTHER

NCT03344692 - Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter